BACKGROUND:Lonafarnib (LNF) is a protein farnesyl transferase (FTase) inhibitor that has shown synergistic activity with taxanes in preclinical models and early stage clinical trials. Preclinical findings suggested tubulin acetylation and FTase expression levels may be important determinants of drug sensitivity that would help identify patient populations more likely to benefit from this regimen. This pilot study evaluated the biological effects of LNF and docetaxel (DTX) combination therapy in refractory solid tumors by comparing pretreatment and post-treatment tumor biopsies. METHODS:Patients with histologically confirmed locally advanced or metastatic solid malignancies refractory to standard therapies or with no effective therapies available were eligible. Patients were randomized to 1 of 4 dosing cohorts: 1) 30 mg/m², 100 mg; 2) 36 mg/m², 100 mg; 3) 30 mg/m², 150 mg; or 4) 36 mg/m², 150 mg of DTX intravenously weekly, LNF orally twice daily, respectively. RESULTS: Of the 38 patients enrolled, 36 were treated, and 29 were evaluable for toxicity and response assessment. The combination of LNF and DTX was tolerated in all cohorts with the exception of a 28% incidence of grade 3/4 diarrhea, which was manageable with aggressive antidiarrheal regimens. Seven patients derived clinically meaningful benefit from this combination treatment; these patients had significantly lower basal FTase-beta mRNA expression levels than the mean study population level (P < .05). Correlation of clinical benefit with tubulin acetylation content as well as basal acetyl-tubulin content were evaluated. However, no significant correlation was found. CONCLUSIONS: Despite the small number of patients, these findings support our preclinical mechanistic studies and warrant further clinical investigations using FTase-beta mRNA expression as a potential predictive biomarker to select for an enriched patient population to study the effects of taxane and FTase inhibitor combination therapies. Cancer 2011
RCT Entities:
BACKGROUND:Lonafarnib (LNF) is a protein farnesyl transferase (FTase) inhibitor that has shown synergistic activity with taxanes in preclinical models and early stage clinical trials. Preclinical findings suggested tubulin acetylation and FTase expression levels may be important determinants of drug sensitivity that would help identify patient populations more likely to benefit from this regimen. This pilot study evaluated the biological effects of LNF and docetaxel (DTX) combination therapy in refractory solid tumors by comparing pretreatment and post-treatment tumor biopsies. METHODS:Patients with histologically confirmed locally advanced or metastatic solid malignancies refractory to standard therapies or with no effective therapies available were eligible. Patients were randomized to 1 of 4 dosing cohorts: 1) 30 mg/m², 100 mg; 2) 36 mg/m², 100 mg; 3) 30 mg/m², 150 mg; or 4) 36 mg/m², 150 mg of DTX intravenously weekly, LNF orally twice daily, respectively. RESULTS: Of the 38 patients enrolled, 36 were treated, and 29 were evaluable for toxicity and response assessment. The combination of LNF and DTX was tolerated in all cohorts with the exception of a 28% incidence of grade 3/4 diarrhea, which was manageable with aggressive antidiarrheal regimens. Seven patients derived clinically meaningful benefit from this combination treatment; these patients had significantly lower basal FTase-beta mRNA expression levels than the mean study population level (P < .05). Correlation of clinical benefit with tubulin acetylation content as well as basal acetyl-tubulin content were evaluated. However, no significant correlation was found. CONCLUSIONS: Despite the small number of patients, these findings support our preclinical mechanistic studies and warrant further clinical investigations using FTase-beta mRNA expression as a potential predictive biomarker to select for an enriched patient population to study the effects of taxane and FTase inhibitor combination therapies. Cancer 2011
Authors: Thomas B Brunner; Stephen M Hahn; Anjali K Gupta; Ruth J Muschel; W Gillies McKenna; Eric J Bernhard Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: R J Slebos; R E Kibbelaar; O Dalesio; A Kooistra; J Stam; C J Meijer; S S Wagenaar; R G Vanderschueren; N van Zandwijk; W J Mooi Journal: N Engl J Med Date: 1990-08-30 Impact factor: 91.245
Authors: Fadlo R Khuri; Bonnie S Glisson; Edward S Kim; Paul Statkevich; Peter F Thall; Michael L Meyers; Roy S Herbst; Reginald F Munden; Craig Tendler; Yali Zhu; Sandra Bangert; Elizabeth Thompson; Charles Lu; Xue-Mei Wang; Dong M Shin; Merrill S Kies; Vali Papadimitrakopoulou; Frank V Fossella; Paul Kirschmeier; W Robert Bishop; Waun Ki Hong Journal: Clin Cancer Res Date: 2004-05-01 Impact factor: 12.531
Authors: Nabil F Saba; Kelly R Magliocca; Sungjin Kim; Susan Muller; Zhengjia Chen; Taofeek K Owonikoko; Nicholas J Sarlis; Carrie Eggers; Vanessa Phelan; William J Grist; Amy Y Chen; Suresh S Ramalingam; Zhuo G Chen; Jonathan J Beitler; Dong M Shin; Fadlo R Khuri; Adam I Marcus Journal: Head Neck Pathol Date: 2013-07-24
Authors: Peter Makhov; Ji A Sohn; Ilya G Serebriiskii; Rushaniya Fazliyeva; Vladimir Khazak; Yanis Boumber; Robert G Uzzo; Vladimir M Kolenko Journal: Br J Cancer Date: 2020-09-24 Impact factor: 7.640